The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease
Open accessAbstract
Alzheimer’s disease is the most common age-related neurodegenerative disorder. Familial forms of Alzheimer’s disease associated with the accumulation of a toxic form of amyloid-β (Aβ) peptides are linked to mitochondrial impairment. The coenzyme nicotinamide adenine dinucleotide (NAD+) is essential for both mitochondrial bioenergetics and nuclear DNA repair through NAD+-consuming poly (ADP-ribose) polymerases (PARPs). Here we analysed the metabolomic changes in flies overexpressing Aβ and showed a decrease of metabolites associated with nicotinate and nicotinamide metabolism, which is critical for mitochondrial function in neurons. We show that increasing the bioavailability of NAD+ protects against Aβ toxicity. Pharmacological supplementation using NAM, a form of vitamin B that acts as a precursor for NAD+ or a genetic mutation of PARP rescues mitochondrial defects, protects neurons against degeneration and reduces behavioural impairments in a fly model of Alzheimer’s disease. Next, we looked at links between PARP polymorphisms and vitamin B intake in patients with Alzheimer’s disease. We show that polymorphisms in the human PARP1 gene or the intake of vitamin B are associated with a decrease in the risk and severity of Alzheimer’s disease. We suggest that enhancing the availability of NAD+ by either vitamin B supplements or the inhibition of NAD+-dependent enzymes such as PARPs are potential therapies for Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supplementation with the NAD+ precursor NAM rescues mitochondrial defects and behavioural impairments in AD models410 but suppresses dopaminergic neurodegeneration in a Drosophila PD model.411”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [410]
Experimental — accuracy not yet measuredIn the citing paper
“Three studies were drawn from an adolescent population aged 12–18 years, potentially introducing heterogeneity when compared to the student population [46,47,48].”
From Concussion Disrupts Sleep in Adolescents: A Systematic Review and Meta-Analysis (2025) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Human Splicing Finder: an online bioinformatics tool to predict splicing signals
Desmet, F.-O., Hamroun, D., Lalande, M., Collod-Béroud, G., Claustres, M., & Béroud, C. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp215 · Cited by 2,512
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis
Chong, J., Wishart, D. S., & Xia, J. (2019) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.86 · Cited by 2,166
Cited by
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“125 Supplementation with the NAD + precursor NAM rescues mitochondrial defects and behavioural impairments in AD models 410 but suppresses dopaminergic neurodegeneration in a Drosophila PD model.”
Xu, X., Sun, B., & Zhao, C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106314 · Cited by 73
Liu, Y., Guttman, L. C., Dawson, V. L., & Dawson, T. M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116174 · Cited by 72
Chiu, L., Huang, D.-Y., & Lin, W. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04138-z · Cited by 48
Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future
Hu, M.-L., Pan, Y.-R., Yong, Y.-Y., Liu, Y., Yu, L., Qin, D.-L., Qiao, G., Law, B. Y.-K., Wu, J.-M., Zhou, X.-G., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102078 · Cited by 44
Metadata
- Authors
- Yu, Y., Fedele, G., Celardo, I., Loh, S. H. Y., & Martins, L. M.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Loh, Samantha H. Y.
- Martins, L. Miguel
- Venue
- Cell Death & Disease
- Published
- 2021-06-25
- Volume
- 12
- Issue
- 7
- Pages
- 651-651
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC8233423
- OpenAlex
- W3174624813
- Cited by
- 46
- References
- 42
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 10 · 2023: 14 · 2022: 3 · 2021: 1
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-07-20)
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Apollo
- Apollo (cc-by)
- Funders
- RCUK | Medical Research Council (MC_UU_00025/3 (RG94521))
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid-beta toxicity, PARP1, NAD+, nicotinate and nicotinamide metabolism, mitochondrial dysfunction, Drosophila model, neurodegeneration, genetic polymorphism, neuroprotection
- MeSH terms
- Poly (ADP-Ribose) Polymerase-1, Alzheimer Disease, Animals, Behavior, Animal, Disease Models, Animal, Drosophila melanogaster, Humans, Mitochondria, Motor Activity, Mutation, NAD, Nerve Degeneration, Neurons, Niacinamide, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Drosophila Proteins, Animals, Genetically Modified, Metabolomics, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41419-021-03926-y
- The paper
- Yu, Y., Fedele, G., Celardo, I., Loh, S. H. Y., & Martins, L. M. (2021). Parp mutations protect from mitochondrial toxicity in Alzheimer’s disease. Cell Death & Disease. https://doi.org/10.1038/s41419-021-03926-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.